MMF Versus CTX in the Induction Treatment of ANCA Associated Vasculitis

计划入组 60 人 · 首次发布于 2006 年 3 月 13 日

Anti-neutrophil Cytoplasmic Antibody in Interstitial Lung Disease.

计划入组 80 人 · 首次发布于 2020 年 6 月 2 日

Study of NM8074 in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV)

计划入组 12 人 · 首次发布于 2024 年 1 月 26 日

Avacopan(Tavneos)

C₃₃H₃₅F₄N₃O₂

anti-Pseudomonas antibody

neutrophil promotor (ProMetic)

Cambridge Antibody Technology

New Zealand

Latticon Antibody Therapeutics, Inc

United States

Novel Anti-Infective Technologies, LLC

Lixudebart Shows Promise in Reversing Organ Fibrosis in Phase 2 Trials

Ruxoprubart Receives FDA IND Clearance for Phase II Trials in IgAN and Dermatomyositis

Biotech Execs Face Legal Scrutiny Over Clinical Trial Result Disclosures